BUDA
BUDA JUICE, INC.
Next earnings ≈ Aug 20, 2026 · est. from filing cadence
Last earnings +2.6% on 2026-05-15
$8.75
▼ -3.06%$8.75▲ +7.94%
over 1Y
L $7.16H $10.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.1%
1W+5.3%
1M+1.2%
3M-17.9%
YTD+7.9%
1Y+7.9%
Sell
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 7 analysts
Buy
Real profits and a clean balance sheet, but a 43.8x P/E on flat earnings and single-customer dependence leave the price stretched.
P/E (price / FY diluted EPS) 43.8 · FY2025
The read
Weak on both the fundamentals and the price — little to like at the current level.
Buda Juice is a genuinely profitable micro-cap: FY2025 revenue grew 11.8% to $12.6M, net margin is an unusually high 28.0%, ROE is 94.5%, and the balance sheet is clean (liabilities/equity 0.33x, $1.84M cash, only $1.23M total liabilities). For a B2B juice producer, those margins and returns are impressive and the operation is not in any distress. That is the bull case, and it is real.
The problem is that the stock price already more than reflects it. At $8.75 the shares trade at 43.8x FY diluted EPS of $0.20 and 8.7x sales — rich multiples for a business whose earnings are not growing. Despite the 11.8% revenue gain, net income actually slipped 1.1% ($3.57M→$3.53M), diluted EPS was flat at $0.20, and operating cash flow fell 20.7% to $3.15M. Gross margin compressed from 46.2% to 44.6% on rising citrus costs, and SG&A jumped 28.8% partly on IPO-prep spend. Paying a 40x+ multiple for zero earnings growth is a poor risk/reward; the growth-adjusted view does not support the price.
Is BUDA a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 9 @ ~1.27 est
- Short put 8 @ ~0.75 est
debit $52max +$48max −$52BE 8.48
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | $11.3M | $12.6M |
| Gross profit | $5.21M | $5.63M |
| Operating income | $3.41M | $3.45M |
| Net income | $3.57M | $3.53M |
| Diluted EPS | $0.20 | $0.20 |
| Net margin | 31.7% | 28.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$108M
EV / EBITDA29.3
EV / Sales8.6
EV / FCF37.2
P / FCF37.9
PEG (trailing)—
Earnings yield3.2%
FCF yield2.6%
Quality & risk
ROIC (est.)72.9%
Free cash flow$2.90M
Total debt—
Net cash$1.84M
Altman Z-Score59.37 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Earnings results2026-05-15
Item 2.02: released Q1 2026 results, first earnings report since Jan IPO
- 10-Q Quarterly report2026-05-14
First 10-Q as public co (period Mar 31, 2026) post-January IPO
- 10-K Annual report2026-03-26
FY25 revenue +11.8% to $12.6M but citrus costs cut margin to 44.6%, net -1.4%
- 8-K Reg FD disclosure2026-01-22
Reg FD/other-events disclosure tied to completion of the January IPO
- 8-K Officer / director change2026-01-09
New officer/director appointments and material agreement ahead of IPO
- S-1/A Securities registration2026-01-06
- S-1/A Securities registration2025-12-18
- S-1/A Securities registration2025-12-12
- S-1/A Securities registration2025-12-01
Recent filings
all on EDGAR ↗CERTFiling2026-05-21open ↗8-A12BFiling2026-05-21open ↗8-KPeriod ending 2026-05-132026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗S-8Filing2026-04-21open ↗SCHEDULE 13GFiling2026-04-02open ↗SCHEDULE 13GFiling2026-04-02open ↗SCHEDULE 13GFiling2026-04-02open ↗10-KPeriod ending 2025-12-312026-03-26open ↗SCHEDULE 13G/AFiling2026-03-04open ↗3Period ending 2026-01-092026-02-20open ↗3Period ending 2026-01-092026-02-20open ↗
Frequently asked
- Is BUDA JUICE, INC. (BUDA) a buy?
- BUDA currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Real profits and a clean balance sheet, but a 43.8x P/E on flat earnings and single-customer dependence leave the price stretched.
- What is BUDA's fair value?
- A Modified-Graham model based on BUDA's SEC fundamentals estimates a fair value of about $3.82. It is an estimate from reported earnings, not a price target.
- Is BUDA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, BUDA currently appears overvalued relative to its SEC-grounded earnings power.
- What is BUDA JUICE, INC.'s quality score?
- BUDA scores 68.09803921568627/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002079720, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/3/2026, 4:36:01 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 12:36 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.